Risk of cancer and serious disease in Danish patients with urgent referral for serious non-specific symptoms and signs of cancer in Funen 2014-2021

被引:2
|
作者
Gronnemose, Rasmus Birkholm [1 ]
Hansen, Per Syrak [1 ]
Worsoe Laursen, Soren [2 ]
Gerke, Oke [3 ,4 ]
Kjellberg, Jakob [5 ]
Lykkegaard, Jesper [6 ]
Thye-Ronn, Clara [1 ]
Hoilund-Carlsen, Poul Flemming [4 ]
Thye-Ronn, Peter [1 ]
机构
[1] Odense Univ Hosp, Svendborg Hosp, Diagnost Ctr, Svendborg, Denmark
[2] Danish Canc Soc, Copenhagen, Denmark
[3] Odense Univ Hosp, Dept Nucl Med, Odense, Denmark
[4] Univ Southern Denmark, Fac Hlth Sci, Dept Clin Res, Odense, Denmark
[5] Danish Ctr Social Sci Res, VIVE, Copenhagen, Denmark
[6] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
DIAGNOSTIC INTERVALS; GENERAL-PRACTICE; SURVIVAL; SWEDEN; UK; PATHWAY; GUIDELINES; AUSTRALIA; DENMARK; NORWAY;
D O I
10.1038/s41416-024-02620-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIn 2011, as the first European country, Denmark introduced the non-organ-specific cancer patient pathway (CPP) for patients presenting with non-specific symptoms and signs of cancer (NSSC). The proportion of patients with cancer over time is unknown.MethodsA retrospective cohort study of all patients with a NSSC-CPP investigational course in the province of Funen to the Diagnostic Centre in Svendborg from 2014 to 2021 was performed to evaluate the proportion of patients with cancer and serious disease over time.ResultsA total of 6698 patients were referred to the NSSC-CPP of which 20.2% had cancer. While the crude referral rate increased from 114 per 100,000 people in 2014 and stabilised to around 214 in 2017-2021, the cancer detection rate of the total yearly new cancers in Funen diagnosed through the NSSC-CPP in DC Svendborg increased from 3 to 6%.ConclusionsWith now high and stable conversion and crude referral rates, the NSSC-CPP is one of the largest CPPs in Denmark as measured by the number of new cancer cases found. Similar urgent referral programmes in other countries might fill an unmet medical need for patients presenting with serious non-specific symptoms and signs of cancer in general practice.
引用
收藏
页码:1304 / 1315
页数:12
相关论文
共 50 条
  • [31] Undergoing Diagnostic Evaluation for Possible Cancer Affects the Health-Related Quality of Life in Patients Presenting with Non-Specific Symptoms
    Moseholm, Ellen
    Rydahl-Hansen, Susan
    Lindhardt, Bjarne Orskov
    PLOS ONE, 2016, 11 (02):
  • [32] HOW LONG DO PATIENTS IN THE UK GET TREATED FOR NON-SPECIFIC RESPIRATORY SYMPTOMS BY GENERAL PRACTITIONERS BEFORE THEY ARE DIAGNOSED WITH LUNG CANCER?
    Iyen-Omofoman, B.
    Tata, L.
    Hubbard, R.
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2011, 65 : A191 - A191
  • [33] Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
    Higashiyama, Ryoko Inaba
    Horinouchi, Hidehito
    Kuchiba, Aya
    Matsumoto, Yuji
    Murakami, Shuji
    Goto, Yasushi
    Kanda, Shintaro
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Ohe, Yuichiro
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3185 - 3191
  • [34] Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
    Ryoko Inaba Higashiyama
    Hidehito Horinouchi
    Aya Kuchiba
    Yuji Matsumoto
    Shuji Murakami
    Yasushi Goto
    Shintaro Kanda
    Yutaka Fujiwara
    Noboru Yamamoto
    Yuichiro Ohe
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 3185 - 3191
  • [35] A UK population-based case-control study of blood tests before cancer diagnosis in patients with non-specific abdominal symptoms
    Rafiq, Meena
    White, Becky
    Barclay, Matthew
    Abel, Gary
    Renzi, Cristina
    Lyratzopoulos, Georgios
    BRITISH JOURNAL OF CANCER, 2025, 132 (05) : 450 - 461
  • [36] How Long Do Patients In The United Kingdom Get Treated For Non-Specific Respiratory Symptoms By General Practitioners Before They Are Diagnosed With Lung Cancer?
    Iyen-Omofoman, B.
    Tata, L.
    Hubbard, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [37] Health-related quality of life in patients with non-specific symptoms that undergo diagnostic investigations for cancer: The impact of socio-demographic and medical characteristics
    Larsen, E. Moseholm
    Rydahl-Hansen, S.
    Lindhardt, B. O.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S223 - S223
  • [38] Whole-Body 18F-FDG PET/CT Is Superior to CT as First-Line Diagnostic Imaging in Patients Referred with Serious Nonspecific Symptoms or Signs of Cancer: A Randomized Prospective Study of 200 Patients
    Lebech, Anne-Mette
    Gaardsting, Anne
    Loft, Annika
    Graff, Jesper
    Markova, Elena
    Bertelsen, Anne Kiil
    Madsen, Jan Lysgard
    Andersen, Kim Francis
    von Benzon, Eric
    Helms, Morten
    Mathiesen, Lars R.
    David, Kim P.
    Kronborg, Gitte
    Kjaer, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (07) : 1058 - 1064
  • [39] A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables
    Makito Miyake
    Hideyasu Matsuyama
    Satoshi Teramukai
    Fumie Kinoshita
    Isao Yokota
    Hiroaki Matsumoto
    Keiji Shimada
    Mitsuru Kinjyo
    Tatsuro Shimokama
    Koji Okumura
    Masaya Yomenori
    Hideki Enokida
    Masayuki Nakagawa
    Yasushi Nakai
    Kiyohide Fujimoto
    International Journal of Clinical Oncology, 2020, 25 : 1364 - 1376
  • [40] A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables
    Miyake, Makito
    Matsuyama, Hideyasu
    Teramukai, Satoshi
    Kinoshita, Fumie
    Yokota, Isao
    Matsumoto, Hiroaki
    Shimada, Keiji
    Kinjyo, Mitsuru
    Shimokama, Tatsuro
    Okumura, Koji
    Yomenori, Masaya
    Enokida, Hideki
    Nakagawa, Masayuki
    Nakai, Yasushi
    Fujimoto, Kiyohide
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (07) : 1364 - 1376